Zanubrutinib Plus Rituximab In First-Line Mcl Therapy

Zanubrutinib plus rituximab in first-line MCL therapy

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Michael Williams on Lenalidomide Plus Rituximab in First Line MCL

Acalabrutinib and rituximab as first-line therapy for older patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Leslie on Sequencing Zanubrutinib in MCL

Dr. Leslie on the Benefits With Zanubrutinib in MCL

Highlights on first-line treatment of Mantle Cell Lymphoma: Primary results from SHINE

European Society for Medical Oncology (ESMO)

Acalabrutinib & Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma - Blood Cancers Library

GRACE - Global Resource for Advancing Cancer Education

Fitting Zanubrutinib into the Treatment Landscape for Mantle Cell Lymphoma

Targeted Oncology

Acalabrutinib plus venetoclax and rituximab in MCL & the importance of chemotherapy-free regimens

VJHemOnc – Video Journal of Hematology & HemOnc

Bendamustine/Rituximab as Induction Therapy in MCL

Targeted Oncology

First results of a prospective bendamustine/rituximab trial in patients with MCL

Dr. Wang on the Toxicity of Ibrutinib, Acalabrutinib, and Zanubrutinib in MCL

Dr. Tam on Zanubrutinib Vs Ibrutinib Research in Mantle Cell Lymphoma

Acalabrutinib plus venetoclax and rituximab in the treatment of MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Villa on Induction Therapy With Bendamustine/Rituximab in MCL

Treatment approaches for older patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Which patients with MCL could benefit most from ibrutinib plus rituximab in the front-line setting?

Martin Dreyling, MD: Efficacy of First-Line Ibrutinib in MCL

American Society of Hematology

First-Line Treatment for Mantle Cell Lymphoma

Targeted Oncology

Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCL